Ardelyx says long-term analysis supports Xphozah safety in dialysis patients

Ardelyx, Inc.

Ardelyx, Inc.

ARDX

0.00
  • Ardelyx presented a post hoc analysis at NKF Spring Clinical Meetings on May 7, 2026, assessing long-term safety of XPHOZAH in adults with chronic kidney disease on dialysis.
  • Analysis pooled data from two open-label studies, including an 18-month extension trial and a 26-week trial, in patients whose phosphorus remained uncontrolled or who could not tolerate phosphate binders.
  • Results indicated XPHOZAH lowered serum phosphate without clinically meaningful shifts in other electrolytes.
  • Review also found no meaningful changes in nutrition-related biomarkers, body mass, or blood pressure over extended treatment.
  • Readout supports positioning of XPHOZAH as add-on therapy with a differentiated mechanism for dialysis patients who do not reach targets on binder regimens.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ardelyx Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605070801PRIMZONEFULLFEED9715456) on May 07, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.